R 1479

Drug Profile

R 1479

Alternative Names: R-1479; RO 1048297

Latest Information Update: 27 Sep 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Argenta Discovery; Roche
  • Developer Roche
  • Class Antivirals; Nucleosides; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 27 Sep 2006 Discontinued - Phase-I for Hepatitis C treatment in United Kingdom (unspecified route)
  • 27 Sep 2006 Discontinued - Phase-I for Hepatitis C treatment in USA (unspecified route)
  • 27 Sep 2006 Discontinued as per oral presentation from Roche at the 232nd American Chemical Society National Meeting (232nd-ACS-2006,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top